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 Abstract 
CD28 and CTLA-4 are members of a family of Immunoglobulin-related receptors that are 
responsible for various aspects of T cell immune regulation. The family includes CD28, CTLA-
4 and ICOS as well as other proteins including PD-1, BTLA and TIGIT. These receptors have 
both stimulatory (CD28, ICOS) as well as inhibitory roles (CTLA-4, PD-1, BTLA and TIGIT) in 
T cell function. Increasingly these pathways are targeted as part of immune modulatory 
strategies to treat cancers, referred to generically as immune checkpoint blockade, and 
conversely to treat autoimmunity and CTLA-4 deficiency. Here we focus on the biology of the 
CD28/CTLA-4 pathway as a framework for understanding the impacts of therapeutic 
manipulation of this pathway. 
 
1. Molecular and cell biology of the CTLA-4 pathway 
 
CTLA-4 and CD28 share two ligands, CD80 and CD86 
Cytotoxic T Lymphocyte antigen 4 (CTLA-4) (CD152) and CD28 are homologous receptors 
expressed by both CD4+ and CD8+ T cells, which mediate opposing functions in T cell 
activation. Both receptors share a pair of ligands expressed on the surface of antigen 
presenting cells (APCs). CD28 interacts with the CD80 dimer with relatively high affinity and 
the CD86 monomer with lower affinity, mediating T cell co-stimulation in conjunction with T cell 
receptor (TCR) signals. In contrast, interactions of the ligands with CTLA-4 serve to inhibit T 
cell responses, although the precise mechanisms are not fully understood. CTLA-4 interacts 
with both ligands with higher affinity and avidity than CD28 1-3 with CTLA-4-CD80 forming the 
highest avidity interaction and CD28-CD86 the weakest (Figure 1A). Amongst several 
possibilities, this raises the concept that CTLA-4 can compete with CD28 for ligand binding 
and thereby act as an antagonist of CD28-mediated co-stimulation 4,5. These interactions are 
thought to take place at the immune synapse between T cells and APCs where CTLA-4 has 
been shown to recruit CD80 thereby limiting its interactions with CD28 6,7. 
 
Whilst the biophysical characteristics of CD80 and CD86 are well defined, their functional 
differences are less clear and the ligands are often referred to together as B7 molecules or 
CD80/CD86.  Both ligands are found on antigen presenting cells such as dendritic cells and B 
cells, although they have different expression patterns, inducibility and kinetics  8-10. Knockout 
mice show impaired immune responses consistent with reduced CD28 co-stimulation, with 
CD86 deficiency arguably demonstrating a more severe phenotype 9. There is considerable 
variation in ligand expression making generalisation difficult, CD86 is often expressed 
constitutively on dendritic cells (DC) and is induced to high levels following inflammatory 
stimuli. In contrast CD80 is thought to be upregulated later by DC. Human peripheral blood 
monocytes express CD86 and not CD80, whereas some human T cells can express both 
CD80 and CD86 under different conditions of activation 11,12. Thus, at present, differences 
between the two ligands revolve mostly around different expression patterns, whereas clear 
functional distinctions have yet to emerge. 
 
Cell biology of CD28 
Perhaps the most surprising feature of CD28 and CTLA-4 is that whilst they share the same 
ligands, they have opposing functions. CD28 is the archetypal co-stimulatory molecule 
involved in the activation of T cells upon binding to either CD80 or CD86. Co-stimulatory 
signals from the CD28 cytoplasmic tail result from interactions with a number of signaling 
molecules including the p85 subunit of PI3 kinase, the Src family kinase Lck, IL-2 inducible 
family kinase Itk, protein kinase C theta and adaptor proteins such as Grb2 and GADS 13-16. 
These signals result in the activation of transcription factors such as NF-κB and AP-1, which 
are important in functional outcomes including IL-2 production and T cell survival. The ability of 
CD28 to activate NF-κB and AP-1 pathways aligns well with the concept that AP-1 is important 
in avoiding unresponsive exhausted states 17 which can occur in the absence of CD28 
costimulation. Indeed, there is considerable overlap between the exhausted gene signature 
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seen in CD8 T cells, resulting from an inability to recruit AP-1, and with that seen in CD4 T cell 
anergy 17.    
 
In addition to the activation of signaling pathways such as PI3K, AP-1, NF-κB and others, 
CD28 is increasingly thought to be important in remodeling of the actin cytoskeleton. CD28 
activates actin-regulators such as Vav-1, cofilin-1 and RLTPR 18 and actin remodeling initiated 
by co-stimulation has been shown to be required for full TCR signaling 19. The close link 
between CD28 and the actin cytoskeleton has been further highlighted in a recent study 
characterizing CD28 interaction with capZIP, a regulator of the actin cytoskeleton. This 
demonstrated capZIP requirement for CD28 co-stimulation-dependent IL-2 production 20. 
Effects on gene regulation are also triggered via the CD28-inducible transcription factor DEC1, 
required for efficient regulation of CD4+ T cell activation pathways 21 and the expression of 
histone acetyl transferase Ezh2, which is responsible for maintaining the regulatory T cell 
(Treg) program 22. Thus CD28 signaling pathways are important for both effector T cell 
activation and Treg function.  
 
 
Cell biology of CTLA-4 
Whilst CD28 is constitutively expressed on the plasma membrane and co-stimulates T cells, 
CTLA-4 is predominantly found in intracellular vesicles in FoxP3+ Treg cells or activated 
conventional T cells. This localization is due to the constitutive endocytosis of CTLA-4 from the 
plasma membrane and results in approximately 90% of CTLA-4 being intracellular 23,24. The 
endocytosis of CTLA-4 is extremely rapid, with more than 80% of surface CTLA-4 being 
internalised within five minutes 25. Once internalised, CTLA-4 molecules appear to be either 
recycled to the plasma membrane or degraded in lysosomal compartments (Figure 1B), 
however, the details of this process and its functional significance are not yet fully understood. 
 
The post-endocytic fate and control of CTLA-4 trafficking is still poorly characterized, although 
experiments show that CTLA-4 lacking its 36-amino acid cytoplasmic tail is predominantly 
located at the cell surface 26. A number of studies have therefore focused on identifying 
partners that interact with the cytoplasmic tail of CTLA-4 and on defining the role of its 
cytoplasmic domain. CTLA-4 endocytosis is dependent on clathrin due to its interaction with 
the μ2 subunit of the clathrin adaptor protein complex AP2 24,27 and is also dependent upon 
dynamin. AP2 targets the cytoplasmic tyrosine containing YVKM motif of CTLA-4 and can be 
disengaged when this motif is tyrosine-phosphorylated upon T cell activation 24,28. However, 
the immunological settings where the CTLA-4–AP-2 interaction is disrupted are unclear since 
activated T cells and Treg continue to endocytose CTLA-4 25. The cytoplasmic domain 
sequence and trafficking behavior of CTLA-4 are highly conserved in mammals whereas some 
animals such as fish lack this endocytic motif 5,29,30 resulting in predominantly surface 
expression. This suggests that endocytosis may be a later adaptation of CTLA-4. Overall, 
CD28 and CTLA-4 differ profoundly in sub-cellular location despite binding to the same ligands 
and, given the conservation of these features, it seems likely they are pivotal to the functioning 
of the system. 
 
The significance of CTLA-4 trafficking was recently highlighted in patients with 
Lipopolysaccharide-responsive and beige-like anchor protein (LRBA) deficiency 31. This 
BEACH domain containing protein 32 appears to regulate CTLA-4 turnover and it co-localizes 
predominantly with recycling (Rab11+) endosomes 31. Loss of LRBA leads to increased CTLA-
4 degradation with associated autoimmunity, indicating that LRBA may inhibit CTLA-4 
trafficking to lysosomes and promote its recycling. This may be achieved through LRBA 
binding to the YVKM consensus sequence of CTLA-4 (Figure 1B). Additional control of CTLA-
4 trafficking and cellular distribution may also be mediated via interaction with the 
TRIM/LAX/Rab8 complex, which is involved in the post-Golgi transport of CTLA-4 to the cell 
surface 33. More recently, CTLA-4 interactions involving PKC-eta and PIX-PAK pathway have 
also been reported. These interactions appear to modulate Treg-APC interactions: PKC-eta 
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deficient Treg are associated with impaired depletion of CD86 from APCs by Treg and 
increased Treg motility 34. 
 
Trans-endocytosis: a cell-extrinsic molecular mechanism of CTLA-4 function 
A number of different models have been proposed to explain the mechanism of CTLA-4 
function. The simplest of these involves competition between CD28 and CTLA-4 for ligand 
binding 4, which has been proposed alongside other cell-intrinsic inhibitory signaling models 
26,35,36
.  However, whilst CD4 T cells from CTLA-4 deficient mice have a hyper-activated, 
disease-causing phenotype, the presence CTLA-4 expressing cells in chimeras can prevent 
disease and normalise the phenotype of CTLA-4 deficient cells via a dominant, cell-extrinsic 
mechanism 37.  
 
One molecular mechanism that is consistent with a dominant cell-extrinsic role for CTLA-4 is 
the physical capture of CD80 and CD86, and their subsequent removal from APCs: a process 
known as trans-endocytosis 38 (Figure 2A). Trans-endocytosis requires T cell recognition of 
peptide and represents an antigen specific mechanism for controlling CD80 and CD86 
expression levels on APC. Whilst the molecular mechanisms underlying trans-endocytosis 
itself are still largely unknown, the CTLA-4 pathway is not the only receptor-ligand pair that 
utilises such a pathway. Other examples include the Notch-Delta pathway 39,40, where binding 
of Delta (ligand) allows subsequent removal of Notch (receptor) from the adjacent cell. Similar 
examples operating in the absence of ectodomain cleavage, include the gap junction protein 
connexin-43 41, adhesion junctions via VE-cadherin 42 receptor tyrosine-kinases Eph-ephrin 
interaction 43 and CD47-SHPS-1 44. Although these examples are present in varied biological 
systems, their overall similarity suggests that a conserved molecular machinery capable of 
removing membrane bound molecules from neighboring cells exists. 
 
In summary, CTLA-4 is a highly endocytic molecule that binds to two distinct ligands, CD80 
and CD86, leading to their removal from opposing cells. By utilizing trans-endocytosis CTLA-4 
can act as an immune regulatory mechanism by directly reducing the ability of APC to 
stimulate via CD28. This concept helps explain why a stimulatory and an inhibitory receptor 
share the same ligands and embraces the endocytic nature of CTLA-4. Taken together, this 
model suggests that the CD28/ CTLA-4 system functions as a rheostat that can tune T cell 
activation up or down. 
 
 
2. CD28 and CTLA-4: a volume control on T cell responses? 
 
The use of a random repertoire of antigen receptors by T cells provides effective coverage for 
the recognition of evolving pathogens. However, it generates a significant problem: that of 
preventing such receptors recognising self-tissues. Such self-reactivity can lead to potentially 
fatal autoimmune conditions including type-I diabetes, inflammatory bowel disorders, 
autoimmune cytopaenias and others.  Whilst T cell selection in the thymus can remove some 
of these self-reactive specificities, it is incomplete for a variety of reasons 45-47. Therefore 
significant numbers of potentially autoreactive T cells are present in the circulation of healthy 
individuals, at frequencies similar to other antigen specificities 48. Indeed recent evidence 
suggests that tolerance to some tissue-restricted self-antigens cannot be achieved by deletion 
and relies on the presence of regulatory T cells 49. Thus, whilst thymic selection mitigates T 
cell self-reactivity, additional controls are required that involve the CD28/CTLA-4 system.  
 
CD28 function: Turning up the volume  
The requirement for CD28 to co-stimulate T cell activation emerged from studies by Schwartz 
and Jenkins 50. Here, antigen specific T cells entered an unresponsive state, termed T cell 
anergy, in response to TCR stimuli in the absence of a “second signal”. This signal was 
subsequently identified as coming from the CD28 receptor interacting with CD80 or CD86. 
Since these ligands are up-regulated by a variety of inflammatory signals, (Figure 2B) CD28 
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signaling provides information on the inflammatory context or “danger” accompanying TCR 
recognition. Importantly, CD28 co-stimulation appears to be additive with signals via the TCR 
enhancing commitment to, as well as more rapid, cell division 51. Moreover, the requirement 
for CD28 co-stimulation is related to strength of TCR signaling 52 such that strong TCR 
stimulation requires less co-stimulation 53-55. Thus, weak TCRs (such as those that are self-
reactive) may be effectively controlled by constraining the availability of CD28 co-stimulation. 
These concepts relating to control of CD28 co-stimulation become significant when 
considering how CTLA-4 might function to quantitatively limit CD28 signaling 56 thereby 
controlling self-reactive and tumour-reactive T cells in the absence of inflammation.  
 
The importance of CD28 signaling in driving T cell proliferative responses has been strikingly 
reinforced by the recent identification of CD28 mutations in T cell leukaemias that increase its 
affinity for ligands. Here, point mutations with increased ligand affinity as well as direct CTLA-
4-CD28 fusions have been observed generating high affinity CD28 variants 57,58, which 
presumably are less effectively out-competed by CTLA-4. To date, a large body of work 
indicates that CD28 signals drive critical T cell effector functions by increasing the magnitude 
of T cell responses, stimulating metabolic changes 59,60 as well as enhancing T cell 
differentiation 61,62 and survival 63. CD28 signals also contribute to enhanced cytokine 
production, influence T cell migration 64 and memory T cell responses to infections 65,66. Given 
these potent activating functions, it is apparent that effective control of CD28 co-stimulation is 
essential and can be provided by CTLA-4. 
 
CTLA-4: Turning down the volume  
The observation of fatal autoimmunity in CTLA-4 knockout mice 67,68 resulting from the release 
of self-reactive T cells 69 illustrated that CTLA-4 was a critical negative regulator of T cell 
responses. T cells isolated from knockout mice showed high levels of activation markers 
including CD25. Whilst the initial interpretation of this activated T cell phenotype focused on 
the possibility that CTLA-4 mediated an inhibitory signal preventing T cell activation 70, 
accumulating evidence now points to an important role for CTLA-4 in mediating the 
suppressive functions of Treg. Indeed early experiments indicated that the major autoimmune 
phenotype of CTLA-4 deficient mice could be prevented by the presence of CTLA-4 
expressing cells in mixed chimeras 37. This observation has been supported by a number of 
other experiments (see 5) and recently a series of conditional and inducible CTLA-4 deletion 
experiments have confirmed that the major phenotype is consistent with an effector function 
for CTLA-4 on Treg 71-73. These data demonstrate that CTLA-4 on Treg can control the activity 
of other cells (such as APCs or naïve T cells) thereby, controlling fatal autoimmunity (Figure 
2A).  
 
Whilst, CTLA-4 on Treg is clearly important in preventing autoimmunity, its expression is also 
induced on activated T cells. Evidence from knockout mice demonstrates a more severe 
phenotype in complete CTLA-4 knockouts compared to Treg specific knockouts, indicating an 
important role for CTLA-4 in conventional T cells 72. However, the function of CTLA-4 in non-
Treg cells can also be cell extrinsic, suggesting they might use the same mechanism as Treg 
74,75
 and activated Tcon can carry out trans-endocytosis 38. Nonetheless, cell-intrinsic functions 
of CTLA-4 controlling the homeostatic expansion of conventional T cells have been observed 
in vivo, although in vitro responses to stimulation were found to be similar between WT and 
knockout conventional T cells 73. 
 
It is also clear that CTLA-4 and CD28 directly influence Treg homeostasis. For example, 
CD28-deficient mice, or those where ligands are blocked, have reduced Treg numbers due to 
altered Treg generation and peripheral survival 76-79. Conversely, the loss of CTLA-4 from Treg 
promotes their expansion via increased CD28 signaling 80,81. Thus, both CD28 and CTLA-4 
profoundly impact the generation, maintenance and function of Treg. This intimate connection 
between CD28 and CTLA-4 function means that it is difficult to understand manipulation of one 
receptor without considering the impact on the other. Indeed, it is arguable that understanding 
For personal use only.on November 22, 2017. by guest  www.bloodjournal.orgFrom 
the impact of CTLA-4 manipulation is best appreciated in terms of its ultimate effect on CD28 - 
CD80/CD86 interactions. 
 
3. Targeting the CTLA-4 pathway: lessons from the clinic 
 
Targeting the CD28/CTLA-4 pathway using antibodies and fusion proteins is of considerable 
interest in the treatment of cancer and autoimmune diseases. Since CTLA-4 limits immune 
responses to self-tissues, augmenting this pathway represents a treatment option for 
autoimmunity whereas suppressing this has the potential to stimulate anti-self-responses 
towards tumours. The potential for the immunological rejection of cancer by harnessing 
immune responses was first realised using anti-CTLA-4 antibodies, and has resulted in 
exponential activity in this area 82.  
 
Initially, murine cancer models demonstrated that anti-CTLA-4 antibody treatment resulted in 
tumour regression and relative resistance to re-inoculation with cancer 83. Less immunogenic 
cancers were, however, unresponsive to anti-CTLA-4 therapy unless GM-CSF producing 
vaccines were co-administered 84. Importantly, enhanced anti-tumour responses following 
CTLA-4 blockade were associated with autoimmunity. This was illustrated by CD8 T cell 
mediated depigmentation in melanoma models 85, immune-mediated prostatitis following 
vaccination against prostate cancer-specific antigens 86 and the generation of anti-double 
stranded DNA antibodies 87. Based upon the efficacy of CTLA-4 blockade in animal models 
anti-CTLA-4 antibodies were developed for clinical use. Ipilimumab, a recombinant human 
immunoglobulin (Ig) G1 monoclonal antibody, and tremelimumab, a human IgG2 monoclonal 
antibody (previously known as ticilimumab) have both been trialed in a range of advanced 
stage cancers. It is clear that ipilimumab potently blocks the interaction of CTLA-4 with its 
ligands by binding to the MYPPPY motif, which is critical for this interaction 88. Reports from 
human trials in melanoma, non-small cell lung cancer, mesothelioma, prostate, ovarian, breast 
and urothelial cancer treatment have shown efficacy 89-108. Alongside the benefits in tumour 
control, these trials nonetheless demonstrate a broad range of immune related adverse events 
(irAEs) occurring in 60-65% of patients. irEAs most commonly effect the skin, gastrointestinal 
(GI) tract, liver and endocrine organs 109. Additionally, autoimmunity has been reported in 
almost all other organs including the liver, eyes, nervous system, lungs, heart, kidneys, and 
joints 89-108,110,111. The breadth of irAEs is therefore consistent with the biological role of CTLA-4 
in the maintenance of polyclonal immune self-tolerance. 
 
Further evidence for a role of CTLA-4 in the control of polyclonal auto-reactive T cells has 
come from examining the circulating TCR repertoire following anti-CTLA-4 therapy. Increased 
diversity of the TCR repertoire occurs following treatment 112, is associated with irAE frequency 
113
 and polyclonal T cell expansion predates and predicts irAEs 114. This data is consistent with 
the idea that CTLA-4 blockade allows the expansion and activation of new T cell clones and 
fits with the idea that self-reactive T cells are present in healthy individuals 48,115 and are 
prevented from expanding by CTLA-4-mediated control of CD80/CD86 116.  
 
The fact that CTLA-4 blockade enables immune responses to cancers and healthy self-tissues 
indicates that significant recognition of self-antigens exists within our immune repertoire. This 
is supported by data from heterozygous loss-of-function mutations in the CTLA-4 gene. 
Individuals with these mutations present with an autosomal dominant syndrome of complex 
autoimmunity and immunodeficiency 81,117. This phenotype has many similarities to anti-CTLA-
4 antibody treatment and includes enteropathy, autoimmune cytopenias, haemolytic anaemia, 
thyroid disease, arthritis, psoriasis, granulomatous lung disease and lymphocytic infiltration of 
non-immune organs. Furthermore, a second CTLA-4 deficiency syndrome caused by 
autosomal recessive mutations in the LRBA gene is associated with an earlier onset, but 
phenotypically similar autoimmune syndrome 31,118,119, consistent with the role played by LRBA 
in the trafficking of CTLA-4 31 (Figure 1B). The similarities in wide-ranging autoimmunity 
between genetic deficiency in the CTLA-4 pathway and the impact of anti-CTLA-4 treatments 
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are striking and reaffirm the central role for CTLA-4 in the maintenance of self tolerance seen 
in animal studies. 
 
The concept that CTLA-4 deficiency leads to a CD28 driven disease is also supported in 
humans by the effect of treatment with the CTLA-4-Ig fusion protein, abatacept. This drug has 
an established role in the treatment of autoimmune disorders, including rheumatoid arthritis 120, 
where it is viewed through the lens of blocking the CD28 co-stimulation pathway. In contrast, 
in CTLA-4 deficiency syndromes, abatacept is viewed as a CTLA-4 replacement therapy. 
Nonetheless, the functional effects are the same in that CD80 and CD86 ligand availability is 
diminished. The fact that CTLA-4- and LRBA-deficient patients respond to abatacept 31,121 is 
consistent with the concept that these diseases are driven by excessive CD28 co-stimulation 
and in agreement with the fundamental biology of CTLA-4, as described above.  
 
Individuals with a mutation in a single allele of CTLA-4 are highly susceptible to autoimmunity, 
raising the possibility that more subtle variations in the level of CTLA-4 in the general 
population may influence responses to treatment. Indeed, non-pathogenic polymorphisms in 
CTLA-4 that alter the expression of CTLA-4 influence an individual’s lifetime risk for the 
development of cancer and autoimmune disorders 122. Taken together these findings illustrate 
that CTLA-4 expression has a pivotal role in balancing immune responses against self-tissues, 
and therefore in regulating both autoimmune and anti-cancer responses. 
 
The impact of CTLA-4 blockade on Treg biology  
Since Treg constitutively express CTLA-4 at high levels, anti-CTLA-4 therapy would be 
expected to have the greatest effect upon these cells. Data from human trials are mixed but an 
increased absolute number of circulating FoxP3+ CD4 Treg have been observed in some 
studies 104,123,124. Similarly, CTLA-4 haplo-insufficiency results in either preserved or increased 
Treg numbers, due to lack of CTLA-4 and resultant increased CD28 signaling 81,117,125. Indeed 
the role of CD28 signaling has been exploited in Treg expansion via the use of CD28-agonist 
antibodies. Whilst initial trials of this strategy were associated with significant inflammatory 
side effects, recent efforts have shown promise 126,127. 
 
Whilst Treg express CTLA-4 at higher levels, activated conventional T cells do express CTLA-
4 and there is additional evidence from cancer therapies to suggest conventional T cell CTLA-
4 may have an important role in self-tolerance. Anti-CTLA-4 treatment combined with Treg 
depletion was shown to be more effective at inducing both anti-tumour responses and 
autoimmunity in animal models 128. Also, using selective blockade of CTLA-4 on Treg or 
conventional T cell, it was demonstrated that Treg CTLA-4 blockade alone could not induce 
antitumor immunity, although it could augment the anti-tumour responses induced by CTLA-4 
blockade of conventional T cells 129. These experiments suggest that CTLA-4 expressed by 
conventional T cells is important in control of polyclonal immune self-tolerance, and the greater 
number of conventional T cells may compensate for their lower levels of CTLA-4 expression 
compared to Treg, when considering the functional impact of CTLA-4. 
 
Despite the fact that limiting CTLA-4 function can drive an increase in Treg numbers there are 
indications that reducing tumour-infiltrating Tregs may be important in determining the 
response to immunotherapy (Figure 2C). A reduction in tumour infiltrating FoxP3+ CD4 Treg 
was observed in one study following anti-CTLA-4 treatment 95 (Figure 2D), although not in 
another 98. However, a possible mechanism of Treg control by anti-CTLA-4 therapies is Treg 
depletion via antibody dependent cellular cytotoxicity (ADCC). Here, anti-CTLA-4 antibodies 
bound by FcR-IV expressing intra-tumoural macrophages results in removal of Treg 130 
(Figure 2D).  
 
CTLA-4 and the microbiome 
One interesting observation from clinical blockade of CTLA-4 is that the most frequent and 
earliest sites of irAE are at the microbe-rich barriers of the skin and gut 131 suggesting either 
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that CTLA-4 has a particularly important role at these sites, or its biology is influenced by 
microbial exposure. Fluctuating levels of antibodies against commensal GI microbes were 
observed in patients following anti-CTLA-4 treatment 132 suggesting dysregulated mucosal 
immunity with CTLA-4 blockade. This interaction of the GI microbiome and CTLA-4 function 
has had considerable attention recently given that tumour control and effector immune 
responses following anti-CTLA-4 therapy are impaired in germ-free or antibiotic exposed mice 
133
. Reconstitution of the mouse GI microbiome with specific Bacteroides species or with 
transplantation of Bacteroides-predominant faecal microbes from patients restored anti-tumour 
responses. Improved tumour responses following anti-CTLA-4 therapy are associated with 
particular microbial populations and also with a reduced incidence of colitis in mice 133 and 
patients 134. Similarly, individuals with CTLA-4 deficiency also tend to experience immune 
targeting of microbe-rich sites, including the skin and gut, however, studies of microbiota have 
yet to be reported. Taken together these findings suggest that the microbial environment in the 
gut modulates the impact of CTLA-4 activity in the control of both distant tumour and local self-
tissue responses. 
 
Correlations between poor anti-tumour responses, higher peripheral Treg and gut homing 
lymphocyte numbers along with specific microbiome clusters have been described. In patients 
with a microbiome cluster associated with better clinical responses, greater up-regulation of 
ICOS (which is associated with more robust clinical responses) was observed on CD4 cells 
following treatment 134. Treg from mice raised under germ free conditions were found to be 
impaired in their capacity to suppress T cell proliferation and the CD25+ CD4 cells from 
mesenteric lymph nodes of germ free mice less frequently express FoxP3 or CTLA-4 135. 
Taken together these findings suggest that the microbiome is important in influencing effector 
and regulatory T cell responses and potentially the dependence of mucosal immune regulation 
upon CTLA-4. However, if CTLA-4 plays a critical role in GI immune regulation a benefit of 
CTLA-4-Ig might have been expected in inflammatory bowel diseases, but this has not been 
demonstrated 136.  
 
Conclusions 
The CTLA-4 pathway is a critical regulator of T cell responses to tissues. The sharing of 
ligands with the stimulatory receptor CD28 establishes a rheostat, capable of tuning T cell 
responses. Accordingly, decreasing CTLA-4 function by antibody blockade, or in CTLA-4 
genetic disorders, increases the availability of ligands for CD28 permitting the activation of 
potentially self-reactive T cells and altering Treg homeostasis.  Furthermore, the high level 
expression of CTLA-4 on Treg and the emerging cell biology of this pathway continue to offer 
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Figure 1 – Schematic of CTLA-4 cell biology: (A) CTLA-4 and CD28 receptors share two 
ligands CD80 and CD86. CD80 is a dimeric high affinity ligand and CD86 is a monomeric 
lower affinity ligand for both receptors. CTLA-4 has a higher affinity and avidity for CD80 than 
CD86. The relative affinities go from high to low from left to right. (B) CTLA-4 expressed in T- 
cells is highly endocytic. CTLA-4 is constitutively expressed in Treg or induced following T cell 
activation via CD28 and TCR signaling. In the absence of the ligand, CTLA-4 is mainly found 
in intracellular compartments following clathrin-mediated endocytosis mediated through CTLA-
4 interaction with the AP2 molecule. The AP2 (μ2 subunit) binds to the tyrosine-based (YVKM) 
motif of the cytoplasmic domain of CTLA-4 and mediates rapid internalization. LRBA and AP1 
proteins have also been found to bind to the YVKM motif on CTLA-4, which appear to impose 
different fates on CTLA-4. LRBA may mediate recycling of CTLA-4 to the plasma membrane, 
whereas AP1 may mediate CTLA-4 trafficking to lysosomal compartments resulting in 
subsequent degradation. 
 
Figure 2 – CTLA-4 function and the impact of immune checkpoint blockade: (A) In health, 
regulatory T cells express CTLA-4, which binds CD80 and CD86 expressed on antigen 
presenting cells (APCs). CTLA-4 binds to CD80 and CD86 with higher affinity and avidity than 
does CD28, preventing Tcon stimulation through CD80/CD86 interaction with CD28. Removal 
of CD80/CD86 ligands by trans-endocytosis results in impaired costimulation of T cells via 
CD28, resulting in immune regulation. (B) When the immune system is stimulated in the 
presence of inflammatory/innate immune stimuli, APCs up-regulate the expression of 
CD80/CD86 overcoming their control by Treg, enabling co-stimulation and the proliferation of 
T cells. (C) In the tumour microenvironment, CD80/CD86 are controlled by Treg and the 
abundance of Treg leads to the suppression of immune responses. (D) Anti-CTLA-4 
antibodies bind to CTLA-4 molecules with high affinity leading to Treg depletion or functional 
blockade resulting in enhanced T cell activation and immunological responses to cancer.  The 
impacts of CTLA-4 blockade can be mediated by a variety of mechanisms: prevention of trans-
endocytosis increasing CD80/CD86 levels on APCs, direct Treg cytotoxicity and antibody 
dependent cellular cytotoxicity mediated by FcR-IV expressing intra-tumoural macrophages. 
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